The CRISPR CFO transition took effect on October 19, 2026, when CRISPR Therapeutics promoted Andrew J. Silver to replace Raju Prasad as chief financial officer. Prasad resigned to pursue external opportunities and is expected to remain an employee until a date on or before November 30, 2026.
Key Takeaways
- Silver became CFO immediately and also assumed the principal financial officer and principal accounting officer roles.
- CRISPR said Prasad’s resignation did not result from a disagreement over its operations, accounting or financial controls.
- Silver joined the company in October 2018 and had served as senior vice president of finance since January 2025.
Table of Contents
- CRISPR CFO transition separates role change from departure
- Silver brings experience across the finance function
- Employment agreement sets salary and equity terms
- Conclusion
CRISPR CFO transition separates role change from departure
CRISPR Therapeutics’ October 19 leadership filing confirms that Prasad resigned as CFO that day, while his employment is expected to continue for a limited period. The distinction means Silver has already taken over the finance leadership role rather than waiting for Prasad’s departure from the company.
The company said Prasad’s decision was not the result of any disagreement involving its operations, policies or practices. That statement explicitly covered financial statements, accounting judgments, internal control over financial reporting and disclosure controls.
| Item | Details |
|---|---|
| Annual base salary | $515,000. |
| Target annual bonus | 45% of annual base salary. |
| One-time promotion award | 25,000 restricted stock units. |
| Equity vesting date | Second anniversary of the grant date, subject to continued service. |
Silver brings experience across the finance function
Silver’s appointment is an internal promotion after eight years at CRISPR Therapeutics. His responsibilities have included strategic finance, treasury, financial planning and analysis, accounting and reporting, tax and financial operations.
Before joining CRISPR, Silver spent more than 10 years at Ernst & Young, most recently as a senior manager in assurance services, where he became a certified public accountant. His appointment places the CFO, principal financial officer and principal accounting officer responsibilities with an executive already familiar with the company’s finance operations.
Employment agreement sets salary and equity terms
CRISPR Therapeutics’ wholly owned subsidiary entered into a new employment agreement with Silver dated October 19. His compensation includes a base salary, eligibility for an annual performance bonus and a one-time restricted stock unit award tied to continued service.
The target bonus is not a guaranteed payment, and Silver’s 2026 bonus will be prorated to reflect the effective date of his promotion. The equity award is scheduled to vest in full after two years, subject to his continued service.
Conclusion
Silver’s appointment is already effective. The next specified transition milestone is the end of Prasad’s employment, expected on or before November 30, 2026; the filing does not give a precise departure date.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
